


**IN THE CLAIMS:**

1. (Currently amended) A compound comprising ~~Compounds of the~~ formula I



wherein in which

$R^1, R^2, R^3,$

$R^4, R^5$  each, independently of one another, are selected from the group consisting of ~~denote~~ H, A, OH, OA, alkenyl, alkynyl,  $\text{NO}_2$ ,  $\text{NH}_2$ , NHA,  $\text{NA}_2$ , Hal, CN, COOH, COOA, -OHet, -O-alkylene-Het, -O-alkylene- $\text{NR}^8\text{R}^9$ ,  $\text{CONR}^8\text{R}^9$ ,  $\text{CH(OH)-A}$  and ~~or~~  $\text{-C(=O)-A}$

two adjacent radicals selected from  $R^1, R^2, R^3, R^4, R^5$  together also selected from the group consisting of ~~denote~~  $\text{-O-CH}_2\text{-CH}_2\text{-}$ ,  $\text{-O-CH}_2\text{-O-}$ ,  $\text{-O-CH}_2\text{-CH}_2\text{-O-}$ ,  $\text{-O-CA}_2\text{-O-}$  and ~~or~~  $\text{-O-CF}_2\text{-O-}$

$R^6, R^7$  each, independently of one another, are selected from the group consisting of ~~denote~~ H, A, Hal, OH, OA and ~~or~~ CN,

$R^8, R^9$  each, independently of one another, are ~~denote~~ H or alkyl having 1-6 C atoms, wherein in which one or two  $\text{CH}_2$  groups may be replaced by O or ~~and/or~~ N atoms,

Het comprises ~~denotes~~ a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O or ~~and/or~~ S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, COOA, CN or carbonyl oxygen (=O),

A comprises ~~denotes~~ alkyl having 1 to 10 C atoms, wherein ~~in which~~, in addition, 1-7 H atoms may be replaced by F or ~~and/or~~ chlorine,

X, X' each, independently of one another, is ~~denote~~ NH or is absent,

Hal is selected from the group consisting of ~~denotes~~ F, Cl, Br and ~~or~~ I,

and pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

2. (Currently amended) The compound ~~Compounds~~ according to Claim 1, wherein ~~in which~~

X is ~~denotes~~ NH or is absent,

X' is ~~denotes~~ NH,

and pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

3. (Currently amended) The compound ~~Compounds~~ according to Claim 1 ~~or 2~~ wherein ~~in which~~

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> each, independently of one another, are selected from the group consisting of ~~denote~~ H, A, OH, OA, NO<sub>2</sub>, NH<sub>2</sub>, NHA, NA<sub>2</sub>, Hal, CN, -OHet, -O-alkylene-Het, -O-alkylene-NR<sup>8</sup>R<sup>9</sup>, CH(OH)-A and ~~or~~ -C(=O)-A,

two adjacent radicals selected from  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$  together also are selected from the group consisting of ~~denote~~  $-O-CH_2-CH_2-$ ,  $-O-CH_2-O-$ ,  $-O-CH_2-CH_2-O-$ ,  $-O-CA_2-O-$  and ~~or~~  $-O-CF_2-O-$

and pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

4. (Currently amended) The compound ~~Compounds~~ according to Claim 1 ~~one or more of Claims 1-3~~ wherein in which

Het comprises ~~denotes~~ a monocyclic saturated heterocycle having 1 to 3 N, O or and/or S atoms, which is unsubstituted or may be monosubstituted by COOA or A,

and pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

5. (Currently amended) The compound ~~Compounds~~ according to Claim 1 ~~one or more of Claims 1-4~~ wherein in which

$R^6$ ,  $R^7$  are ~~denotes~~ H,

and pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

6. (Currently amended) The compound ~~Compounds~~ according to Claim 1 ~~one or more of Claims 1-5~~ wherein in which

$R^8$ ,  $R^9$  are ~~denote~~ H,

and pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

7. (Currently amended) The compound ~~Compounds~~ according to Claim 1 ~~one or more of Claims 1-6~~ wherein in which

X is ~~denotes~~ NH or is absent,

X' is ~~denotes~~ NH,

$R^1, R^2, R^3, R^4, R^5$  each, independently of one another, are selected ~~from the group consisting of~~ denote H, A, OH, OA, NO<sub>2</sub>, NH<sub>2</sub>, NHA, NA<sub>2</sub>, Hal, CN, -OHet, -O-alkylene-Het, -O-alkylene-NR<sup>8</sup>R<sup>9</sup>, CH(OH)-A and ~~or~~ -C(=O)-A,

two adjacent radicals selected from  $R^1, R^2, R^3, R^4, R^5$  together also are selected from the group consisting of ~~denote~~ -O-CH<sub>2</sub>-CH<sub>2</sub>-, -O-CH<sub>2</sub>-O-, -O-CH<sub>2</sub>-CH<sub>2</sub>-O-, -O-CA<sub>2</sub>-O- and ~~or~~ -O-CF<sub>2</sub>-O-

Het comprises ~~denotes~~ a monocyclic saturated heterocycle having 1 to 3 N, O or ~~and/or~~ S atoms, which is unsubstituted or may be monosubstituted by COOA or A,

$R^6, R^7$  is ~~denote~~ H,

$R^8, R^9$  each, independently of one another, are ~~denote~~ H or alkyl having 1-6 C atoms, wherein in which one or two CH<sub>2</sub> groups may be replaced by O or ~~and/or~~ N atoms,

and pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

8. (Currently amended) The compound ~~Compounds~~ according to Claim 1 ~~one or more of Claims 1-7~~ wherein in which

X is ~~denotes~~ NH or is absent,

X' is ~~denotes~~ NH,

$R^1, R^2, R^3, R^4, R^5$  each, independently of one another, are selected from the group consisting of ~~denote~~ H, A, OH, OA, NO<sub>2</sub>, NH<sub>2</sub>, NHA, NA<sub>2</sub>, Hal, CN, -OHet, -O-alkylene-Het, -O-alkylene-NR<sup>8</sup>R<sup>9</sup>, CH(OH)-A and ~~or~~ -C(=O)-A,

two adjacent radicals selected from  $R^1, R^2, R^3, R^4, R^5$  together also are selected from the group consisting of ~~denote~~ -O-CH<sub>2</sub>-CH<sub>2</sub>-, -O-CH<sub>2</sub>-O-, -O-CH<sub>2</sub>-CH<sub>2</sub>-O-, -O-CA<sub>2</sub>-O- and ~~or~~ -O-CF<sub>2</sub>-O-

$R^6, R^7$  are ~~denote~~ H,

$R^8, R^9$  each, independently of one another, are ~~denote~~ H or alkyl having 1-6 C atoms, wherein ~~in which~~ one or two CH<sub>2</sub> groups may be replaced by O or ~~and/or~~ N atoms,

Het comprises ~~denote~~ piperidinyl, pyrrolidinyl, morpholinyl or piperazinyl, each of which is unsubstituted or monosubstituted by COOA or A,

and pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

9. (Currently amended) The compound ~~Compounds~~ according to Claim 1, selected from the group consisting of

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(2-fluoro-5-trifluoromethylphenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(4-chloro-5-trifluoromethylphenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(2,4-difluorophenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(2,6-difluorophenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(3-fluoro-5-trifluoromethylphenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(4-fluoro-5-trifluoromethylphenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(4-methyl-5-trifluoromethylphenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(2,3,4,5,6-pentafluorophenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(2,4-dibromo-6-fluorophenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(2-fluoro-6-trifluoromethylphenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(2,3,4-trifluorophenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(4-bromo-2,6-difluorophenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(2-fluoro-3-trifluoromethylphenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[2-(1-tert-butylloxycarbonylpiperidin-4-yl)phenyl]urea,

N-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-2,4-dichlorobenzamide,

N-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-4-chloro-5-trifluoromethylbenzamide,

N-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-2-fluoro-5-trifluoromethylbenzamide,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[3-chloro-5-trifluoromethyl-2-(piperidin-4-yloxy)phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[(2-fluoro-5-(2-dimethylaminoethoxy)phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[5-fluoro-2-(piperidin-4-yloxy)phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[4-chloro-5-trifluoromethyl-2-(piperidin-4-yloxy)phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[2-(piperidin-4-yloxy)phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[2-fluoro-5-(2-diethylaminoethoxy)phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[2-fluoro-5-[2-(piperidin-1-yl)ethoxy]phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[4-fluoro-2-(2-dimethylaminoethoxy)phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[4-fluoro-2-(2-diethylaminoethoxy)phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[3-chloro-4-[2-(morpholin-4-yl)ethoxy]phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[4-fluoro-2-[2-(morpholin-4-yl)ethoxy]phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[3-chloro-4-(2-dimethylaminoethoxy)phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[3-chloro-4-(2-diethylaminoethoxy)phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[4-chloro-2-(2-dimethylaminoethoxy)phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[2-chloro-5-(2-diethylaminoethoxy)phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[3-trifluoromethyl-6-[3-(morpholin-4-yl)propoxy]phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(2-{{2-[(2-methoxyethyl)methylamino]ethoxy}-5-trifluoromethylphenyl}urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(4-{{2-[(2-methoxyethyl)methylamino]ethoxy}-3-trifluoromethylphenyl}urea,



1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[3-trifluoromethyl-4-(2-methylaminoethoxy)phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[5-trifluoromethyl-2-(2-methylaminoethoxy)phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[3-trifluoromethyl-4-[3-(morpholin-4-yl)propoxy]phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[4-(1-methylpiperidin-4-yloxy)-3-trifluoromethylphenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[4-(1-methylpiperidin-4-ylmethoxy)-3-trifluoromethylphenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[4-(piperidin-4-ylmethoxy)-3-trifluoromethylphenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[2-(piperidin-4-yl-methoxy)-5-trifluoromethylphenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[2-(1-methylpiperidin-4-ylmethoxy)-5-trifluoromethylphenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(2-fluorophenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(3-trifluoromethylphenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(3-bromo-5-trifluoromethylphenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-benzo-1,3-dioxol-5-ylurea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(2,2-dimethylbenzo-1,3-dioxol-5-yl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(3-trifluoromethoxyphenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(4-trifluoromethylphenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(2-methoxy-5-trifluoromethylphenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(3-tert-butylphenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(3-isopropylphenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(3-acetylphenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(4-methoxy-5-trifluoromethylphenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[3-(2,2,2-trifluoro-1-hydroxyethyl)phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(3-ethylphenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(2,2-difluorobenzo-1,3-dioxol-5-yl)urea, and


1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(3-methoxy-5-trifluoromethylphenyl)urea, 471;

and pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.


10. (Currently amended) A process ~~Process~~ for the preparation of compounds of the formula I ~~according to Claims 1-9~~ and pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers thereof, comprising reacting characterised in that

a) ~~for the preparation of compounds of the formula I in which X, X<sup>2</sup> denote NH,~~

a compound of the formula II



wherein ~~in which~~ R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> and R<sup>9</sup> have the meanings indicated in Claim 1,  
~~is reacted~~ with a compound of the formula III




wherein ~~in which~~ R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> have the meanings indicated in Claim 1,

or

b) ~~for the preparation of compounds of the formula I in which X is absent and X' denotes NH,~~

reacting a compound of the formula II is ~~reacted~~ with a compound of the formula IV



wherein ~~in which~~ R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> have the meanings indicated in Claim 1,

and L comprises ~~denotes~~ Cl, Br, I or a free or reactively functionally modified OH group,

or and/or

a base or acid of the formula I is converted into one of its salts.

11. (Currently amended) A pharmaceutical composition ~~Medicaments~~ comprising at least one compound of the formula I according to Claim 1 ~~and/or~~ pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients ~~or and/or~~ adjuvants.

12. (Currently amended) A method of treatment of diseases comprising inhibiting, regulating or modulating kinase signal transduction comprising administering to a patient in need thereof, a pharmaceutical composition according to Claim 11 ~~Use of compounds according to Claim 1~~

~~——— and pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios,~~

~~for the preparation of a medicament for the treatment of diseases~~

~~in which the inhibition, regulation and/or modulation of kinase signal transduction plays a role.~~

13. (Currently amended) The method ~~Use~~ according to Claim 12, wherein said ~~where the~~ kinases are selected from the group consisting of the tyrosine kinases and Raf kinases.

14. (Currently amended) The method ~~Use~~ according to Claim 13, wherein said ~~where the~~ tyrosine kinases are selected from the group consisting of TIE-2, VEGFR, PDGFR, FGFR and ~~and/or~~ FLT/KDR.

15. (Canceled) ~~Use according to Claim 13 of compounds according to Claim 1, and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios,~~

~~for the preparation of a medicament for the treatment of diseases which are influenced by inhibition of tyrosine kinases by the compounds according to Claim 1.~~

16. (Canceled) ~~Use according to Claim 15 for the preparation of a medicament for the treatment of diseases which are influenced by inhibition of TIE-2, VEGFR, PDGFR, FGFR or and/or FLT/KDR by the compounds according to Claim 1.~~

17. (Currently amended) The method Use according to Claim 12 ~~wherein said 15 or 16, where the disease comprises to be treated~~ is a solid tumour.

18. (Currently amended) The method Use according to Claim 17 ~~wherein said 17, where the~~ solid tumour originates from the group consisting of tumours of the squamous epithelium, the bladder, the stomach, the kidneys, of head and neck, the oesophagus, the cervix, the thyroid, the intestine, the liver, the brain, the prostate, the urogenital tract, the lymphatic system, the stomach, the larynx and ~~and/or~~ the lung.

19. (Currently amended) The method Use according to Claim 17 ~~wherein said 17, where the~~ solid tumour originates from the group consisting of monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas and breast carcinoma.

20. (Currently amended) The method Use according to Claim 17 ~~wherein said 17, where the~~ solid tumour originates from the group consisting of lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas, colon carcinoma and breast carcinoma.

21. (Currently amended) The method Use according to Claim ~~15 or 16,~~ wherein said ~~where the disease to be treated~~ is a tumour of the blood and immune system.

22. (Currently amended) The method Use according to Claim 21, where the tumour originates from the group of acute myelotic leukaemia, chronic myelotic leukaemia, acute lymphatic leukaemia or and/or chronic lymphatic leukaemia.

23. (Currently amended) The method Use according to Claim 15 ~~or 16~~ ~~for the treatment of a disease~~ wherein in which angiogenesis is implicated.

24. (Currently amended) The method Use according to Claim 23, wherein said ~~where the~~ disease is an ocular disease.

25. (Currently amended) The method Use according to Claim ~~24 15 or 16~~ ~~for the treatment of~~ wherein said ocular disease is selected from the group consisting of retinal vascularisation, diabetic retinopathy, age-induced macular degeneration and and/or inflammatory diseases.

26. (Currently amended) The method Use according to Claim 25, wherein said ~~where the~~ inflammatory disease originates from the group consisting of rheumatoid arthritis, psoriasis, contact dermatitis and delayed hypersensitivity reactions.

27. (Currently amended) The method Use according to Claim ~~12 15 or 16~~ ~~for the treatment of~~ wherein said disease comprise bone pathologies, wherein said ~~where the~~ bone pathology originates from the group consisting of osteosarcoma, osteoarthritis and rickets.

28. (Currently amended) The method according to Claim 12 ~~Use of compounds of the formula I according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of solid tumours, where a therapeutically effective amount of a compound of the formula I~~ wherein said pharmaceutical composition is administered in combination with a compound from the group consisting of 1) oestrogen



receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6) prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor and 10) another angiogenesis inhibitor.

29. (Currently amended) The method according to Claim 12 Use of compounds of the formula I according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of solid tumours, where a therapeutically effective amount of a compound of the formula I wherein said pharmaceutical composition is administered in combination with radiotherapy and a compound from the group 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6) prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor and 10) another angiogenesis inhibitor.

30. (Currently amended) The method according to Claim 12 Use according to Claim 15 or 16 for the preparation of a medicament for the treatment of diseases which are based on disturbed TIE-2 activity,

~~where a therapeutically effective amount of a compound according to Claim 1~~ wherein said pharmaceutical composition is administered in combination with a growth-factor receptor inhibitor.

31. (Canceled) ~~Use according to Claim 12 or 13 of compounds of the formula I~~

~~for the preparation of a medicament for the treatment of diseases which are caused, mediated and/or propagated by Raf kinases.~~



32. (Currently amended) The method Use according to Claim 13 wherein said 31, ~~where the~~ Raf kinase is selected from the group consisting of A-Raf, B-Raf and Raf-1.

33. (Currently amended) The method Use according to Claim 12 wherein said 31, ~~where the~~ diseases are selected from the group of hyperproliferative and non-hyperproliferative diseases.


34. (Currently amended) The method Use according to Claim 12 wherein said 31 or 33, ~~where the~~ disease is cancerous cancer.

35. (Currently amended) The method Use according to Claim 12 wherein said 31 or 33, ~~where the~~ disease is non-cancerous.

36. (Currently amended) The method Use according to Claim 31, 33 or 35, wherein said ~~where the~~ non-cancerous diseases are selected from the group consisting of psoriasis, arthritis, inflammation, endometriosis, scarring, benign prostatic hyperplasia, immunological diseases, autoimmune diseases and immunodeficiency diseases.

37. (Currently amended) The method Use according to ~~one of~~ Claims 31, 33 and 34, wherein said ~~where the~~ diseases are selected from the group consisting of brain cancer, lung cancer, squamous cell cancer, bladder cancer, gastric cancer, pancreatic cancer, hepatic cancer, renal cancer, colorectal cancer, breast cancer, head cancer, neck cancer, oesophageal cancer, gynaecological cancer, thyroid cancer, lymphoma, chronic leukaemia and acute leukaemia.

38. (Currently amended) A compound ~~Intermediate compounds~~ of the formula I-1



wherein in which

$R^6$ ,  $R^7$  each, independently of one another, are selected from the group consisting of ~~denote~~ H, A, Hal, OH, OA and ~~or~~ CN,

$R^8$ ,  $R^9$  each, independently of one another, are ~~denote~~ H or A,

$R^{10}$  is ~~denotes~~  $\text{NH}_2$  or  $\text{NO}_2$ ,

A in each case, independently of one another, is ~~denotes~~ alkyl having 1 to 10 C atoms, wherein in which, in addition, 1-7 H atoms may be replaced by F or ~~and/or~~ chlorine,

Hal are selected from the group consisting of ~~denotes~~ F, Cl, Br and ~~or~~ I,

and solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

39. (Currently amended) The compound ~~Intermediate compounds~~ according to Claim 38

wherein in which

$R^6$ ,  $R^7$  are ~~denote~~ H

$R^8$ ,  $R^9$  are ~~denote~~ H,

and solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.